(United States, Nevada, Las Vegas), DelveInsight’s “Bone Metastases – Pipeline Insight, 2023” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Bone Metastases pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Bone Metastases Pipeline Report
-
Over 10+ companies and 10+ pipeline drugs in Bone Metastases are in various stages of development, and their anticipated acceptance in the Bone Metastases market would significantly increase market revenue.
-
Leading Bone Metastases companies developing novel drug candidates to improve the Bone Metastases treatment landscape include Mabwell (Shanghai) Bioscience Co., Ltd., AlaMab Therapeutics, Qilu Pharmaceutical Co., Ltd., Exelixis, Shanghai JMT-Bio Inc., BiologicsMD, Luye Pharma Group Ltd.
-
Promising Bone Metastases pipeline therapies in various stages of development include MW032, ALMB-0168, and many others.
Bone Metastases Overview
Bone metastasis occurs when cancer cells from other parts of the body spread to the bone. The most common area for bone metastasis is the spine. The first symptom a person might experience is bone pain. The most common symptom of bone metastasis is pain. Other symptoms are bone fractures, spinal cord compression, and anemia. Bone metastasis can be diagnosed using laboratory tests, radiographic examinations, CAT scans, MRIs, and biopsy. Bone metastasis treatment can include pain management, radiation, surgery, and medical interventions.
Bone Metastases Pipeline Analysis: Drug Profile
MW032: Mabwell (Shanghai) Bioscience Co., Ltd.
MW032 is a Denosumab biosimilar being developed by Mabwell (Shanghai) Bioscience Co., Ltd. Denosumab is a fully human monoclonal antibody that binds the cytokine RANKL (receptor activator of NFκB ligand), an essential factor initiating bone turnover. RANKL inhibition blocks osteoclast maturation, function, and survival, thus reducing Buergers Disease. MW032 is currently in the Phase III stage of development to treat Bone Metastases from Solid Tumors.
Discover more about the emerging Bone Metastases drugs @ Bone MetastasesDisease Treatment Drugs
Bone Metastases Pipeline Therapies and Key Companies
-
MW032: Mabwell (Shanghai) Bioscience Co., Ltd.
-
ALMB-0168: AlaMab Therapeutics
And many others
Bone Metastases Pipeline Therapeutics Assessment
DelveInsight’s report covers around 10+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Route of Administration
Bone Metastases pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Inhalation
-
Inhalation/Intravenous/Oral
-
Intranasal
-
Intravenous
-
Intravenous/ Subcutaneous
-
NA
-
Oral
-
Oral/intranasal/subcutaneous
-
Parenteral
-
Subcutaneous
Molecule Type
Bone Metastases Products have been categorized under various Molecule types such as
-
Small molecule
-
Cell Therapy
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
Molecule Type
Products have been categorized under various Molecule types such as
-
Antibody
-
Antisense oligonucleotides
-
Immunotherapy
-
Monoclonal antibody
-
Peptides
-
Protein
-
Recombinant protein
-
Small molecule
-
Stem Cell
-
Vaccine
Scope of the Bone Metastases Pipeline Report
-
Coverage: Global
-
Key Bone Metastases Companies: Mabwell (Shanghai) Bioscience Co., Ltd., AlaMabTherapeutics, Qilu Pharmaceutical Co., Ltd., Exelixis, Shanghai JMT-Bio Inc., BiologicsMD, Luye Pharma Group Ltd. and many others.
-
Key Bone Metastases Pipeline Therapies: MW032, ALMB-0168, and many others.
Find out more about the Bone Metastases treatment options in development@ Bone Metastases Clinical Trials
Table of Contents
1. Bone Metastases Introduction
2. Bone Metastases Executive Summary
3. Bone Metastases Overview
4. Bone Metastases Pipeline Therapeutics
5. Bone Metastases Late-Stage Products (Phase III)
6. Bone Metastases Mid-Stage Products (Phase II)
7. Bone Metastases Early Stage Products (Phase I/II)
8. Bone Metastases Preclinical Stage Products
9. Bone Metastases Discovery Stage Products
10. Bone MetastasesTherapeutic Assessment
11. Bone Metastases Inactive Products
12. Bone Metastases Collaborations Assessment- Licensing / Partnering / Funding
13. Bone Metastases Unmet Needs
14. Bone Metastases Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services